Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

PSTI 1.51 -0.02 (-1.31%)
price chart
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Updates On U.S. FDA Study In ...
Before we get into Pluristem Therapeutics Inc. (NASDAQ:PSTI) we would like to draw your attention on a company that released solid news this morning.
New Broker Ratings For Pluristem Therapeutics, Inc. (PSTI)  FTSE News
Pluristem Therapeutics Inc Stock Momentum at Critical Inflection Point
This is a momentum stock rating analysis for Pluristem Therapeutics Inc (NASDAQ:PSTI) . The company has a three bull momentum rating which indicates an inflection point.
Pluristem Therapeutics Inc. 131.8% Potential Upside Now Implied by H.C ...  DirectorsTalk Interviews
Pluristem Therapeutics Inc. (PSTI) Given Buy Rating at HC Wainwright  BBNS
Option Market: Pluristem Therapeutics Inc Risk Hits An Extreme High
This is a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for Pluristem Therapeutics Inc (NASDAQ:PSTI) .
FBR Capital Analyst Bullish on Pluristem Therapeutics Inc. (PTSI) Following ...
FBR Capital analyst Vernon Bernardino weighed in on Pluristem Therapeutics Inc. (NASDAQ:PSTI) following the an announcement that the company plans to initiate a Phase I trial to investigate its PLX-R18 drug.
HC Stocks in the Rumor: Pluristem Therapeutics Inc. (NASDAQ:PSTI), Abbott ...  share market updates (press release)
Pluristem Advances Phase I Study Of PLX-R18 Cells To Treat Insufficient ...  Benzinga
Maxim Weighs In on Anavex Life Sciences Corp. (AVXL), Pluristem Therapeutics ...
Maxim's healthcare analyst Jason Kolbert weighed in today on two names in his coverage universe, Anavex Life Sciences Corp. (NASDAQ:AVXL) and Pluristem Therapeutics Inc. (NASDAQ:PSTI). While Anavex's ANAVEX 2-73 received orphan designation ...
Next Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI)
07/11/2016 - Pluristem Therapeutics, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 3 price target on the stock.
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Went Up 1.32%: South State ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) traded 75399 shares on last trading day with closing price of $1.53. Company gross margin stands at 96.50% whereas its return on investment (ROI) is -43.50%.
Pluristem Therapeutics, Inc. Stock Momentum Hits Weakness
This is a momentum stock rating analysis for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) . The company has a two bull momentum rating which indicates some weakness.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Nails Phase 2 Clinical Trial With ...
The outcome of Pluristem Therapeutics Inc. (NASDAQ: PSTI)'s PLX-PAD in a trial treatment of Duchenne muscular dystrophy has been revealed and it is a positive one.
Pluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6%  Nasdaq
Pluristem Therapeutics, Inc. (PSTI) Current Analyst Ratings  Fiscal Standard
FBR & Co. Reaffirms Outperform Rating for Pluristem Therapeutics Inc. (PSTI)
Pluristem Therapeutics logo Pluristem Therapeutics Inc. (NASDAQ:PSTI)'s stock had its “outperform” rating reiterated by investment analysts at FBR & Co.
Pluristem Therapeutics (PSTI) Announces Positive PLX-PAD Cells Preclinical ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Short Ratio At 6.00  Vanguard Tribune